The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first ...

"In the phase 3 randomized clinical trial, once-daily oral ivarmacitinib (4 or 8 mg) led to significant improvements in the ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

DelveInsight’s "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth ...

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).